Vascular Biogenics

Jilted at the NASDAQ Altar
Risk Management

Jilted at the NASDAQ Altar

A key investor balks at buying IPO shares in Vascular Biogenics, voiding trading in the stock only six days after the biotech firm went public.
By Iris Dorbian | August 12, 2014
Read More